TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05324397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK System
Description: The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study: NCT03629327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 81mg
Description: Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will be randomized to take nothing on a daily basis for a duration of 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 325mg
Description: Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
Study: NCT05163080

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SurVaxM
Description: Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SurVaxM
Description: Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
Study: NCT05134584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: 290μg once daily, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 20mL once daily, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazol
Description: 20mg twice daily for the first 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazol
Description: 20mg twice daily for the first 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: 50mg three times daily for the first 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: 50mg three times daily for the first 10 days
Study: NCT04957485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecovirimat
Description: oral antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smallpox and Mpox Vaccine
Description: vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smallpox and Mpox Vaccine
Description: vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TPOXX Placebo
Study: NCT05335330

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia
Description: The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia
Description: The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia
Description: The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
Study: NCT04771156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
Study: NCT06478420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
Study: NCT04865276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
Description: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
Description: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
Study: NCT06403514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Skills Training (PST)
Description: PST will include self-talk, imagery, goal-setting and arousal regulation (Biofeedback)
Study: NCT05627830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
Study: NCT06077968

Intervention type: BIOLOGICAL
Intervention: Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Description: Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.

Intervention type: BIOLOGICAL
Intervention: Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Description: Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
Study: NCT04166643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHHIP PLUS
Description: Worksite health promotion and occupational health and safety (total worker health)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only control
Description: Education at the start of the project
Study: NCT06318741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.
Description: aerobic exercise on the treadmill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.
Description: Walking at an intensity of 12-13 RPE
Study: NCT04910048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POPOP (preoperative patient optimization program)
Description: A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC (standard of care)
Description: Referral to a dietician for two months of self-directed weight loss
Study: NCT04425967

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pre-operative radiotherapy
Description: pre-operative radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: pre-operative radiotherapy
Description: pre-operative radiotherapy
Study: NCT05100121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive app
Description: In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: During the health dialogues with the nurse, the patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patients health record.
Study: NCT06112093

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
Study: NCT04909450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Matching vehicle control without the drug substance
Study: NCT05800210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CliniMACS Prodigy ® system
Description: Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
Study: NCT05421611

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: STAMARIL
Description: STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.
Study: NCT05005182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate
Study: NCT05421611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII-YFV
Description: SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection.
Study: NCT05005182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05249582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality wireless headset

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Television Condition
Description: Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
Study: NCT05791643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized internal and external coping strategies
Description: A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized internal coping strategies
Description: A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized external coping strategies
Description: A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General internal and external coping strategies
Description: A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General internal coping strategies
Description: A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General external coping strategies
Description: A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General internal coping strategies, relaxation
Description: A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General internal coping strategies, distraction
Description: A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General internal coping strategies, physical activity
Description: A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
Study: NCT05538325

Intervention type: DEVICE
Intervention: Bubble Inclinometer and Digital Pelvic Inclinometer
Description: They are valid and reliable devices to measure the range of motion of the lumbar spine

Intervention type: DEVICE
Intervention: Bubble Inclinometer and Digital Pelvic Inclinometer
Description: They are valid and reliable devices to measure the range of motion of the lumbar spine

Intervention type: DEVICE
Intervention: Bubble Inclinometer and Digital Pelvic Inclinometer
Description: They are valid and reliable devices to measure the range of motion of the lumbar spine
Study: NCT03651349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-001
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
Study: NCT05164289

Intervention type: OTHER
Intervention: Control group
Description: Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75

Intervention type: OTHER
Intervention: EMDR group
Description: Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
Study: NCT06511258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
Study: NCT06131801

Intervention type: OTHER
Intervention: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Description: Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
Study: NCT05058365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dots Curriculum
Description: dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home.
Study: NCT06336005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC6022-0001
Description: Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC6022-0001)
Description: Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts